Premium
Congenital toxoplasmosis from a mother with type 2 diabetes mellitus: A case report
Author(s) -
Sato Shimpei,
Nishida Masakazu,
Nasu Kaei,
Narahara Hisashi,
Norose Kazumi,
Aosai Fumie
Publication year - 2014
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.12477
Subject(s) - medicine , toxoplasmosis , asymptomatic , sulfadiazine , vomiting , toxoplasma gondii , pregnancy , amniotic fluid , gestation , pyrimethamine , umbilical cord , obstetrics , pediatrics , surgery , fetus , malaria , immunology , antibiotics , chloroquine , genetics , antibody , microbiology and biotechnology , biology
A 33‐year‐old woman with type 2 diabetes mellitus ( DM ) was suspected of being primarily infected with T oxoplasma gondii at 12 weeks of gestation ( GW ). Although acetylspiramycin was started at 17 GW , the T . gondii DNA gene was detected in the amniotic fluid at 18 GW . Chemotherapy was changed to pyrimethamine plus sulfadiazine from 20 GW , but was changed back to acetylspiramycin after 2 weeks because of vomiting. Acetylspiramycin was continued until her delivery. DM was controlled well during the pregnancy. An asymptomatic male baby was born by cesarean section at 37 GW , and was treated with acetylspiramycin for 4 weeks because the polymerase chain reaction results of umbilical cord blood were positive. He has developed normally until the present, that is, 6 months of age. Herein, we describe a case report in which symptomatic congenital toxoplasmosis was avoided in a pregnant woman with an immunosuppressive risk due to prompt chemotherapy.